|
"hsu jta"的相关文件
显示项目 11-35 / 88 (共4页)
1 2 3 4 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2018-10 |
Identification of novel Cdc7 kinase inhibitors as anti-cancer agents that target the interaction with Dbf4 by the fragment complementation and drug repositioning approach
|
Cheng, AN;Lo, YK;Lin, YS;Tang, TK;Hsu, CH;Hsu, JTA;Lee, AYL |
| 國家衛生研究院 |
2018-01 |
Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer
|
Hsieh, HP;Hsu, JTA;Yeh, TK;Chen, CT |
| 國家衛生研究院 |
2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
|
Hsieh, HP;Wang, WC;Shiao, HY;Ke, YY;Lin, WH;Hsu, JTA;Chen, CT;Yeh, TK |
| 國家衛生研究院 |
2016-11-29 |
Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design
|
Chang, CF;Lin, WH;Ke, YY;Lin, YS;Wang, WC;Chen, CH;Kuo, PC;Hsu, JTA;Uang, BJ;Hsieh, HP |
| 國家衛生研究院 |
2016-05-19 |
Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses
|
Wang, HY;Hsu, MK;Wang, KH;Tseng, CP;Chen, FC;Hsu, JTA |
| 國家衛生研究院 |
2015-07 |
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations
|
Chen, CT;Hsu, JTA;Lin, WH;Lu, CT;Yen, SC;Hsu, T;Huang, YL;Song, JS;Chen, CH;Chou, LH;Yen, KJ;Chen, CP;Kuo, PC;Huang, CL;Eugene Liu, H;Chao, YS;Yeh, TK;Jiaang, WT |
| 國家衛生研究院 |
2015-01 |
Identification of ligand efficient, fragment-like hits from an HTS library: Structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity
|
Sarvagalla, S;Singh, VK;Ke, YY;Shiao, HY;Lin, WH;Hsieh, HP;Hsu, JTA;Coumar, MS |
| 國立交通大學 |
2014-12-08T15:39:10Z |
Anti-HCV activities of selective polyunsaturated fatty acids
|
Leu, GZ; Lin, TY; Hsu, JTA |
| 國立交通大學 |
2014-12-08T15:19:20Z |
Anti-HCV activities of selective polyunsaturated fatty acids (vol 318, pg 275, 2004)
|
Leu, GZ; Lin, TY; Hsu, JTA |
| 國立交通大學 |
2014-12-08T15:18:14Z |
Inhibition of hepatitis C virus replication by antimonial compounds
|
Hwang, DR; Lin, RK; Leu, GZ; Lin, TY; Lien, TW; Yu, MC; Yeh, CT; Hsu, JTA |
| 國家衛生研究院 |
2014-12 |
BPR-3P0128 inhibits RNA-dependent RNA polymerase elongation and VPg uridylylation activities of Enterovirus 71
|
Balaji, VA;Chen, GW;Hsieh, PT;Horng, JT;Hsu, JTA;Hsieh, HP;Chen, TC;Weng, KF;Shih, SR |
| 國家衛生研究院 |
2014-11-20 |
The combination effects of LiCl and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replication
|
Hung, HC;Shih, SR;Chang, TY;Fang, MY;Hsu, JTA |
| 國家衛生研究院 |
2014-11 |
Reticulon 3 interacts with NS4B of the hepatitis C virus and negatively regulates viral replication by disrupting NS4B self-interaction
|
Wu, MJ;Ke, PY;Hsu, JTA;Yeh, CT;Horng, JT |
| 國家衛生研究院 |
2014-10 |
Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML
|
Hsu, YC;Shiao, HY;Ke, YY;Hsu, JTA;Lin, WH;Chen, CH;Hsieh, HP |
| 國家衛生研究院 |
2014-05 |
Facile identification of dual FLT3-Aurora A inhibitors: A computer-guided drug design approach
|
ChangHsu, Y;Ke, YY;Shiao, HY;Lee, CC;Lin, WH;Chen, CH;Yen, KJ;Hsu, JTA;Chang, C;Hsieh, HP |
| 國家衛生研究院 |
2014-05 |
Cover Picture: Facile identification of dual FLT3–aurora a inhibitors: A computer-guided drug design approach (ChemMedChem 5/2014)
|
Chang Hsu, Y;Ke, YY;Shiao, HY;Lee, CC;Lin, WH;Chen, CH;Yen, KJ;Hsu, JTA;Chang, C;Hsieh, HP |
| 國家衛生研究院 |
2014-02 |
Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle
|
Chiu, SH;Wu, MC;Wu, CC;Chen, YC;Lin, SF;Hsu, JTA;Yang, CS;Tsai, CH;Takada, K;Chen, MR;Chen, JY |
| 國家衛生研究院 |
2014-01-08 |
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer
|
Lin, WH;Yeh, TK;Jiaang, WT;Yen, KJ;Chen, CH;Huang, CT;Yen, SC;Hsieh, SY;Chou, LH;Chen, CP;Chiu, CH;Kao, LC;Chao, YS;Chen, CT;Hsu, JTA |
| 國家衛生研究院 |
2013-12 |
Evolutionarily conserved residues at an oligomerization interface of the influenza A virus neuraminidase are essential for viral survival
|
Mok, CK;Chen, GW;Shih, KC;Gong, YN;Lin, SJ;Horng, JT;Hsu, JTA;Chen, CJ;Shih, SR |
| 國家衛生研究院 |
2013-09-22 |
A novel Aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment [Erratum:International Journal of Biological Sciences. 2013 Apr 29;9(4):403-411]
|
Shionome, Y;Lin, WH;Shiao, HY;Hsieh, HP;Hsu, JTA;Ouchi, T |
| 國家衛生研究院 |
2013-06 |
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)
|
Lin, WH;Hsu, JTA;Hsieh, SY;Chen, CT;Song, JS;Yen, SC;Hsu, T;Lu, CT;Chen, CH;Chou, LH;Yang, YN;Chiu, CH;Chen, CP;Tseng, YJ;Yen, KJ;Yeh, CF;Chao, YS;Yeh, TK;Jiaang, WT |
| 國家衛生研究院 |
2013-04-29 |
A novel Aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment
|
Shionome, Y;Lin, WH;Shiao, HY;Hsieh, HP;Hsu, JTA;Ouchi, T |
| 國家衛生研究院 |
2013-04-07 |
BPR000K, a novel Aurora kinase inhibitor
|
Chao, YS;Hsu, JTA;Chen, CT;Yeh, TK;Pan, SL;Hsieh, HP |
| 國家衛生研究院 |
2013-04-07 |
3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor
|
Ke, YY;Shiao, HY;Hsu, YC;Chang-Chu, Y;Wang, WC;Lee, YC;Lin, WH;Hsu, JTA;Chang, CW;Lin, CW;Yeh, TK;Chao, YS;Coumar, MS;Hsieh, HP |
| 國家衛生研究院 |
2013-04-07 |
Development drug candidate targeting EGFR kinase: DBPR112
|
Sun, HY;Hsu, JTA;Chen, CT;Yeh, TK;Pan, SL;Chao, YS;Hsieh, HP |
显示项目 11-35 / 88 (共4页)
1 2 3 4 > >>
每页显示[10|25|50]项目
|
